D18 is an immunomodulator that acts as a dual TLR7/8 agonist (EC50 = 24 nM for hTLR7; EC50 = 10 nM for hTLR8); it enhances PD-L1 expression via epigenetic regulation, thereby sensitizing tumors to PD-1/PD-L1 blockade; it is also used as a cytotoxic payload in antibody-drug conjugates (ADCs), specifically for the synthesis of ADCHE-S2.